A recent phase 3 study reveals osimertinib combined with chemotherapy offers unprecedented survival rates for patients with advanced EGFR-mutated lung cancer.
Laura Silvius, Managing Editor
Advertisement
Laura Silvius is the managing editor of Pharmacy Times. She is a graduate of Bryn Mawr College and Syracuse University.
Articles by Laura Silvius, Managing Editor
Experts forecast a potential resurgence of measles and other vaccine-preventable diseases in the U.S. due to declining vaccination rates.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Long COVID and Brain Health
2
Radio Frequency Identification is Revolutionizing Medication Management
3
Pharmacist Strategies for Navigating Supplement Use in Patients on TNF Inhibitors
4
Unique Pharmacy Technician Career Ladder Meets the Needs of a Growing Profession
5